Fig. 2From: Caregiver experiences and observations of intrathecal idursulfase-IT treatment in a phase 2/3 trial in pediatric patients with neuronopathic mucopolysaccharidosis IICaregiver-reported pre-trial MPS II signs and symptoms with a prevalence of ≥ 15%. CNS Central nervous system, MPS II Mucopolysaccharidosis IIBack to article page